Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?

Cancer Journal (United States)

Volumn 18, Issue 5, 2012, Pages 390-395

  Lowry, Lisa ^a   Ardeshna, Kirit M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

asymptomatic; Follicular lymphoma; rituximab; watch and wait

Indexed keywords

BETA 2 MICROGLOBULIN; FC RECEPTOR; LACTATE DEHYDROGENASE; RITUXIMAB;

ASYMPTOMATIC DISEASE; BRONCHOSPASM; CANCER GRADING; CANCER PROGNOSIS; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG COST; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HEPATITIS; HUMAN; INFECTION; INFECTION RISK; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT RESPONSE; TUMOR VOLUME; WATCHFUL WAITING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; NEOPLASM GRADING; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 84866904988     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31826aed4f     Document Type: Review

References (33)

1. Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non- Hodgkin's lymphomas of favorable histologic types. Ann Intern Med. 1979;90:10-13.
2. Horning SJ, Rosenberg SA. The natural history of initially untreated lowgrade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471-1475.
3. O'Brien M, Easterbrook P, Powell J, et al. The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. QJM. 1991;80:651-660.
4. Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(suppl 2):11-16.
5. Ganti A, Bociek R, Bierman P, et al. Follicular lymphoma: expanding therapeutic options. Oncology. 2005;19:213-228; discussion 228, 233-236, 239.
6. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1110-1117.
7. Ardeshna K, Smith P, Norton A, et al. Long-term effect of awatch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516-522.
8. Fisher RI, Le BlancM, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23: 8447-8452.
9. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failurefree survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582-1589.
10. Tan D, Rosenberg SA, Levy R, et al. Survival in follicular lymphoma: the Stanford experience, 1960-2003. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 3428.
11. Rohatiner A, Gregory W, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23: 2215-2223.
12. HiddemannW, KnebaM,DreylingM, et al. Frontline therapywith rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005;106:3725-3732.
13. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579-4586.
14. Herold M, Maschmeyer G, Lakner V, et al. Sustained survival advantage after a median follow-up of 5 years for immuno-chemotherapy (R-MCP) versus chemotherapy alone (MCP) in advanced follicular lymphomaVupdate of the OSHO#39 trial. Haematologica. 2010; 95(suppl 2):239. Abstract 0575.
15. McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
16. Colombat P. Rituximab (anti-CD20 monoclonal antibody) as single firstline therapy and molecular evaluation for patients with follicular lymphoma with a low tumor burden: clinical. Blood. 2001;97:101-106.
17. Ardeshna KM, QianW, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood (ASH Annual Meeting Abstracts). 2010. Abstract 6, plenary session.
18. Kahl BS, Hong F, Williams ME, et al. Results of eastern cooperative oncology group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118. Abstract 6.
19. Martinelli G, Hsu Schmitz S-F, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28: 4480-4484.
20. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202-1208.
21. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561-1570.
22. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885-4893.
23. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res. 2008;14:1550-1560.
24. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426-2433.
25. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:5165-5169.
26. Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188-196.
27. Yuen AR, Kamel OW, Halpern J, et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726-1733.
28. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42-51.
29. British National Formulary No. 63.MabThera. Section 8.2.3. March 2012.
30. Deconinck E, Miadi-Fargier H, Pen CL, et al. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics. 2010;28:35-46.
31. Solal-Ce'ligny P, Roy P, Colombat P, et al. Follicular lymphoma International Prognostic Index. Blood. 2004;104:1258-1265.
32. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcFRIIIa gene. Blood. 2002;99:754-758.
33. Lowry L, Pule M, Ardeshna KM, et al. FcgR polymorphisms do not influence response to rituximab in asymptomatic, non-bulky follicular lymphoma; results from Intergroup trial of rituximab vs. "watch and wait". Ann Oncol. 2011;22(suppl 4). Abstract 142.